Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effective. Dr. Raje presented these findings at the 2017 Lymphoma-Myeloma meeting in New York.
Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
